Cargando…

Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission: A Preliminary Report of a Retrospective Cohort Study

The efficient transmission of severe acute respiratory syndrome-2 coronavirus (SARS-CoV-2) from patients to health care workers or family members has been a worrisome and prominent feature of the ongoing outbreak. On the basis of clinical practice and in-vitro studies, we postulated that post-exposu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jin-nong, Wang, Wen-jing, Peng, Bo, Peng, Wei, Zhang, Yi-sheng, Wang, Ya-ling, Wan, Yan, Chang, Jiang, Mao, Ling, Miao, Xiao-ping, Li, Ya-nan, Zhou, Yi-fan, Hu, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Huazhong University of Science and Technology 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260450/ https://www.ncbi.nlm.nih.gov/pubmed/32474860 http://dx.doi.org/10.1007/s11596-020-2203-3

Ejemplares similares

Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19
por: Liu, Lei, et al.
Publicado: (2021)

A trial of arbidol hydrochloride in adults with COVID-19
por: Zhao, Jingya, et al.
Publicado: (2022)

The Antiviral Drug Arbidol Inhibits Zika Virus
por: Fink, Susan L., et al.
Publicado: (2018)

Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment and Consulting Doctor Later: A Retrospective Cohort Study
por: He, Xin-liang, et al.
Publicado: (2021)

Arbidol as a broad-spectrum antiviral: An update
por: Blaising, Julie, et al.
Publicado: (2014)

Arbidol: The current demand, strategies, and antiviral mechanisms
por: Kang, Yue, et al.
Publicado: (2023)

Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals
por: Yang, Chunguang, et al.
Publicado: (2020)

Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
por: Li, Hailong, et al.
Publicado: (2021)

Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China
por: Guo, Yong-zheng, et al.
Publicado: (2020)

Beneficial effect of Arbidol in the management of COVID-19 infection
por: Jie, Xiong, et al.
Publicado: (2021)

Glycomic Analysis Reveals That Sialyltransferase Inhibition Is Involved in the Antiviral Effects of Arbidol
por: Kang, Yue, et al.
Publicado: (2022)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Synthesis and biological activity of water-soluble polymer complexes of arbidol
por: Eropkin, M. Yu., et al.
Publicado: (2010)

Efficacy of arbidol in COVID-19 patients: A retrospective study
por: Wei, Shuo, et al.
Publicado: (2021)

Photocatalytic degradation of COVID-19 related drug arbidol hydrochloride by Ti(3)C(2) MXene/supramolecular g-C(3)N(4) Schottky junction photocatalyst
por: Jin, Dexin, et al.
Publicado: (2022)

Real-world experience of arbidol for Omicron variant of SARS-CoV-2
por: Zhao, Jingya, et al.
Publicado: (2023)

Mechanism of Inhibition of Enveloped Virus Membrane Fusion by the Antiviral Drug Arbidol
por: Teissier, Elodie, et al.
Publicado: (2011)

Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
por: Nojomi, Marzieh, et al.
Publicado: (2020)

Conformational Screening of Arbidol Solvates: Investigation via 2D NOESY
por: Eventova, Varvara A., et al.
Publicado: (2023)

Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
por: Chen, Chang, et al.
Publicado: (2021)

Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
por: Li, Yueping, et al.
Publicado: (2020)

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
por: Wang, Xi, et al.
Publicado: (2020)

Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study
por: Yin, Peng, et al.
Publicado: (2021)

Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats
por: HU, Yunzhen, et al.
Publicado: (2021)

Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection
por: Boriskin, Yury S, et al.
Publicado: (2006)

The Location of the Protonated and Unprotonated Forms of Arbidol in the Membrane: A Molecular Dynamics Study
por: Galiano, Vicente, et al.
Publicado: (2016)

Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo
por: Zhong, Qiong, et al.
Publicado: (2009)

A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019
por: Wang, Xuemei, et al.
Publicado: (2020)

Pre-exposure and Post-exposure Prophylaxis for Dog Bites
por: Joob, Beuy, et al.
Publicado: (2017)

Consensus statement on human immunodeficiency virus pre-exposure prophylaxis in China
por: Xu, Jun-Jie, et al.
Publicado: (2020)

Effect of umifenovir (arbidol) versus standard care on clinical outcome in patients with COVID-19: a retrospective cohort study
por: Yi, Wanwan, et al.
Publicado: (2023)

Pharmacokinetic properties and bioequivalence of two formulations of arbidol: An open-label, single-dose, randomized-sequence, two-period crossover study in healthy chinese male volunteers
por: Liu, Ming-Yan, et al.
Publicado: (2009)

Transmission of Novel Influenza A(H1N1) in Households with Post-Exposure Antiviral Prophylaxis
por: van Boven, Michiel, et al.
Publicado: (2010)

2188. Effectiveness of a Risk-Stratified Measles Post-Exposure Prophylaxis Strategy to Prevent Nosocomial Transmission
por: Seah, Valerie Xue Fen, et al.
Publicado: (2018)

HIV transmission by human bite: a case report and review of the literature—implications for post-exposure prophylaxis
por: Schürmann, Dirk, et al.
Publicado: (2020)

Post-exposure prophylaxis during pandemic outbreaks
por: Moghadas, Seyed M, et al.
Publicado: (2009)

Current perspectives in HIV post-exposure prophylaxis
por: Sultan, Binta, et al.
Publicado: (2014)

COVID-19: Time for Post-Exposure Prophylaxis?
por: Gentile, Ivan, et al.
Publicado: (2020)

Post-exposure prophylaxis with isavuconazole after occupational exposure to Rhizopus
por: Al-Obaidi, Mohanad, et al.
Publicado: (2018)

Responding to the post-pandemic crisis: post-exposure prophylaxis for TB
por: Heffernan, C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_77elrrbv4du4pvrqsjj5di1s45